"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Totect Consumer (continued)
A product that may interact with this drug is: dimethylsulfoxide (DMSO) products applied to the skin.
OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Keep all medical appointments while using this medication. Laboratory and/or medical tests (such as complete blood counts, examination of the injection site) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.
MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist immediately to establish a new dosing schedule.
STORAGE: Not applicable. This medication is given in a clinic and will not be stored at home.
Information last revised May 2014. Copyright(c) 2014 First Databank, Inc.
Additional Totect Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.